Translational gastroenterology and hepatology最新文献

{"title":"Esophageal POEM: the new standard of care.","authors":"Salmaan Jawaid, Peter V Draganov, Dennis Yang","doi":"10.21037/tgh.2019.12.17","DOIUrl":"10.21037/tgh.2019.12.17","url":null,"abstract":"<p><p>Since its introduction into clinical practice nearly a decade ago, per-oral endoscopic myotomy (POEM) has now become an accepted minimally invasive approach for the treatment of achalasia with excellent short- and mid-term clinical outcomes in both treatment naïve and those who have failed prior therapy. POEM is comparable to laparoscopic Heller myotomy (LHM) in terms of efficacy and safety, with less procedural pain and faster recovery time. Recent data also reveals that POEM may be more effective and durable than pneumatic dilation (PD) for the treatment of achalasia, with similar safety profile. Preliminary data on POEM for spastic esophageal disorders (SED) is promising yet scarce. Post-POEM gastroesophageal reflux disease (GERD) is common but asymptomatic in most patients, further highlighting the need for ongoing research in this field and the importance of long-term surveillance of these patients.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"47"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530316/pdf/tgh-05-2019.12.17.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38605376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease.","authors":"Kyle E Robinson,&nbsp;Vijay H Shah","doi":"10.21037/tgh.2019.12.05","DOIUrl":"https://doi.org/10.21037/tgh.2019.12.05","url":null,"abstract":"<p><p>Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) account for the majority of hepatic morbidity and deaths due to cirrhosis in the United States. ALD is an umbrella term for a number of conditions linked to excessive alcohol consumption including simple steatosis, cirrhosis, acute alcoholic hepatitis (AH) with or without cirrhosis, and hepatocellular carcinoma (HCC) as a complication of cirrhosis. Although it presents with histological features resembling alcohol-induced liver injury, NAFLD occurs in patients with little or no history of alcohol consumption. NAFLD is a broad-spectrum term used to describe anything from fat accumulation in hepatocytes without inflammation or fibrosis (simple hepatic steatosis) to hepatic steatosis with a necroinflammatory component (steatohepatitis) with or without associated fibrosis. The pathogenesis is not fully understood for either disease. Development of severe liver disease is highly variable amongst chronic abusers of alcohol. Sex, age, genetics, host microbiome, and behavior are all factors linked to the development of ALD. These factors also contribute to NAFLD, but by contrast, insulin resistance is widely believed to be the main driver of nonalcoholic hepatic steatosis. The mechanism behind the transition from nonalcoholic steatosis to steatohepatitis remains a matter of debate with insulin resistance, oxidative injury, hepatic iron, gut hormones, antioxidant deficiency, and host microbiome all suspected to play part of the role.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"49"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tgh.2019.12.05","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38605378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular biology and immunology of gastric cancer peritoneal metastasis.","authors":"Xiaodan Yao,&nbsp;Jaffer A Ajani,&nbsp;Shumei Song","doi":"10.21037/tgh.2020.02.08","DOIUrl":"https://doi.org/10.21037/tgh.2020.02.08","url":null,"abstract":"<p><p>Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"57"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tgh.2020.02.08","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38505753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse gastric cancer: histologic, molecular, and genetic basis of disease.","authors":"Pritish Iyer, Maitham Moslim, Jeffrey M Farma, Crystal S Denlinger","doi":"10.21037/tgh.2020.01.02","DOIUrl":"10.21037/tgh.2020.01.02","url":null,"abstract":"<p><p>Diffuse gastric cancer (DGC) is a distinct histopathologic and molecular disease, characterized by mutations in CDH1, RHOA, and others. In addition, DGC is associated with familial syndromes, including hereditary DGC and germline mutation in CDH1. Clinically, this subtype of gastric adenocarcinoma is associated with a poor prognosis and possible resistance to available systemic therapies. An understanding of the genetic and molecular underpinnings of DGC may help inform of its clinical behavior and aid in screening, diagnosis, and response to treatment. In this review, we will review the current histologic, molecular, and genetic landscape of DGC and its relevance to clinical practice.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"52"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530323/pdf/tgh-05-2020.01.02.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38605381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of early gastric cancer using image enhanced endoscopy: a systematic approach.","authors":"Masaki Miyaoka,&nbsp;Kenshi Yao,&nbsp;Hiroshi Tanabe,&nbsp;Takao Kanemitsu,&nbsp;Kensei Otsu,&nbsp;Kentaro Imamura,&nbsp;Yoichiro Ono,&nbsp;Satoshi Ishikawa,&nbsp;Tatsuhisa Yasaka,&nbsp;Toshiharu Ueki,&nbsp;Atsuko Ota,&nbsp;Seiji Haraoka,&nbsp;Akinori Iwashita","doi":"10.21037/tgh.2019.12.16","DOIUrl":"https://doi.org/10.21037/tgh.2019.12.16","url":null,"abstract":"<p><p>This paper provides an overview of the principles of a vessel plus surface (VS) classification system to explain the diagnostic system of early gastric cancer using image-enhanced magnifying endoscopy. Furthermore, this paper introduces the magnifying endoscopy simple diagnostic algorithm for gastric cancer (MEADA-G) developed according to the VS classification system, with a description of the procedures performed for diagnosis. In addition to the diagnostic system, white opaque substance (WOS), light blue crest (LBC), white globe appearance (WGA), and vessels within epithelial circle (VEC) patterns, which are representative findings that can be observed in the gastric mucosa by image-enhanced magnifying endoscopy, are also described. Image-enhanced magnifying endoscopy is particularly useful in the diagnosis of differentiated-type early gastric cancer. It is important to use the appropriate clinical strategies based on a comprehensive understanding of the usefulness and limitations of the diagnostic system described in this paper.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"50"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tgh.2019.12.16","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38605379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approach to prevention of non-alcoholic fatty liver disease after liver transplantation.","authors":"Praveen Sharma,&nbsp;Anil Arora","doi":"10.21037/tgh.2020.03.02","DOIUrl":"https://doi.org/10.21037/tgh.2020.03.02","url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver disease and non-alcoholic steatohepatitis (NASH) related cirrhosis is third common indication for liver transplantation (LT). Patients who have NASH related cirrhosis and are candidates for LT often have multiple comorbidities. These comorbidities need to be addressed before and after transplantation as it affects overall survival. Like hepatitis B, hepatitis C, primary biliary cirrhosis, autoimmune hepatitis which recurs after transplantation, NASH also recurs after transplant however the impact of the recurrence on allograft and patient outcomes is unclear. Limited data suggests that it does not affect graft and patient survival. De novo NAFLD which is defined as occurrence of fatty liver in a patient who did not have fatty liver prior to LT can also occur in the allograft of patients transplanted for non-NAFLD liver disease. Obesity, hyperlipidemia, diabetes as well as steroid dose and duration after LT are common predictors of recurrence of NAFLD after transplantation. Studies on prevention and treatment of NASH in post-transplant patients are lacking. Prevention of weight gain, regular exercises, weight reducing surgery, limited steroid use or steroid free regimen have been tried with varying success. Future studies for the prevention of NAFLD/NASH are required especially in post liver transplant patient.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"51"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tgh.2020.03.02","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38605380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next generation sequencing in gastric or gastroesophageal adenocarcinoma.","authors":"Geoffrey Y Ku","doi":"10.21037/tgh.2020.01.09","DOIUrl":"https://doi.org/10.21037/tgh.2020.01.09","url":null,"abstract":"<p><p>Seminal analyses of The Cancer Genome Atlas (TGCA) and Asian Cancer Research Group (ACRG) have provided unprecedented insight into the molecular underpinnings of gastric cancer (GC). At the same time, next generation sequencing (NGS) panels, driven by quantum improvements in DNA sequencing technology and bioinformatics, are now routinely used in standard clinical care and also extensively for research purposes. This review article will discuss the molecular subtypes of GC, the current standard-of-care therapies for GC and the role of NGS in standard care and in research.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"56"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tgh.2020.01.09","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38505752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel immunotherapy strategies for treatment of neuroendocrine neoplasms.","authors":"Taymeyah Al-Toubah, Mauro Cives, Jonathan Strosberg","doi":"10.21037/tgh.2019.12.18","DOIUrl":"10.21037/tgh.2019.12.18","url":null,"abstract":"<p><p>Neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) are a heterogeneous family of neoplasms. Well-differentiated tumors are often slow growing and characterized by low tumor mutational burden. Poorly differentiated NECs are aggressive, with an increased mutational burden and higher propensity to express PD-L1. While the therapeutic landscape for neuroendocrine neoplasms (NENs) has evolved substantially over the past decade, immunotherapy has been unexplored in NENs until recently. Checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 agents, bi-specific tumor-targeting antibodies, and chimeric antigen receptor (CAR) T-cell therapy are examples of treatments that have demonstrated efficacy in other cancers and have recently been investigated in NENs. This review examines the immune landscape of NENs in detail, summarizes recent clinical study results, and discusses potential future directions for immunotherapy.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"54"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530319/pdf/tgh-05-2019.12.18.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38505750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finding the hot spot: identifying immune sensitive gastrointestinal tumors.","authors":"Andre Luiz Pitanga Bastos De Souza","doi":"10.21037/tgh.2019.12.11","DOIUrl":"https://doi.org/10.21037/tgh.2019.12.11","url":null,"abstract":"<p><p>Although researchers have been trying to harness the immune system for over 100 years, the advent of immune checkpoint blockers (ICB) marks an era of significant clinical outcomes in various metastatic solid tumors, characterized by complete and durable responses. ICBs are monoclonal antibodies that target either of a pair of transmembrane molecules in tumors or T-cells involved in immune evasion. Currently 2 ICBs targeting the checkpoint program death 1 (PD-1), nivolumab and pembrolizumab, and one cytotoxic lymphocyte antigen-4 (CTLA-4) inhibitor (ipilimumab) are approved in gastrointestinal malignancies. We review herein the current evidence on predictive biomarkers for ICB response in gastrointestinal tumors. A review of literature based on the National Cancer Institute list of FDA-approved drugs for neoplasms and FDA-approved therapies at the FDA website was performed. An initial literature review was based on the American Association for Clinical Research meeting 2019, the American Society of Clinical Oncology meeting 2019 and the European Society of Medical Oncology 2019 proceedings. A systematic search of PubMed was performed involving MeSH browser terms such as biomarkers, immunotherapy, gastrointestinal diseases and neoplasms. When appropriate, American and British terms were used in the search. The most relevant predictor of response to ICBs is microsatellite instability (MSI) and the data is strongest for colorectal cancer. At least 3 prospective trials show evidence of PD-L1 as a predictive biomarker for ICB response in gastroesophageal malignancies. At least one prospective trial has described tumor mutational burden high (TMB-H), independent of MSI, as predictive of response in anal and biliary tract carcinomas. DNA Polymerase Epsilon (POLE) or delta (POL-D) mutations have been implicated in a subset of MSS colorectal cancer with TMB-H but this biomarker requires prospective validation. There is evolving data based on retrospective observations that gene alterations predicting acquired resistance and hyper-progression. Ongoing clinical research is assessing the role of the human microbiome and RNA-editing complex mutations as predictive biomarkers of response to ICBs. MSI has the strongest predictive power among current biomarkers for ICB response in gastrointestinal cancers. Data continue to accumulate from ongoing clinical trials and new biomarkers are emerging from pre-clinical studies, suggesting that drug combinations targeting pathways complimentary to the PD-1/PD-L1 axis inhibition will define a robust field of clinical research.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"48"},"PeriodicalIF":3.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tgh.2019.12.11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38605377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EUS-RFA of the pancreas: where are we and future directions.","authors":"L. Gollapudi, A. Tyberg","doi":"10.21037/TGH-2019-IE-10","DOIUrl":"https://doi.org/10.21037/TGH-2019-IE-10","url":null,"abstract":"Surgical resection remains the gold standard for pancreatic cancer, high-risk pancreatic neuroendocrine tumors (PNETs) and pancreatic cystic neoplasms (PCNs). However, a majority of pancreatic cancers are unresectable at the time of diagnosis. In addition, surgical resection of pancreatic lesions can be associated with morbidity and mortality. A less-invasive alternative therapeutic intervention to avoid short term and long-term adverse events is desirable, as is a minimally-invasive palliative therapy for unresectable or recurrent pancreatic cancers. Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) allows for selective tissue ablation with minimal injury to the surrounding tissue. EUS-RFA of pancreatic tumors has shown high clinical and technical success with acceptable side effects in pancreatic lesions, lymph nodes, and the celiac plexus. This paper will review the pathophysiology, available technology, safety and efficacy, and future directions of EUS-RFA.","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"1 1","pages":"18"},"PeriodicalIF":3.0,"publicationDate":"2020-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86450429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}